ZYMEWORKS INC. (ZYME) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 37.13M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $37.13M | (m) | (m) |
| 2026-03-31 | (m) | $81.26M | (m) | (m) |
| 2025-12-31 | (m) | $105.97M | (m) | (m) |
| 2025-09-30 | (m) | $134.48M | (m) | (m) |
| 2025-06-30 | (m) | $122.87M | (m) | (m) |
| 2025-03-31 | (m) | $93.38M | (m) | (m) |
| 2024-12-31 | (m) | $76.30M | (m) | (m) |
| 2024-09-30 | (m) | $62.20M | (m) | (m) |
| 2024-06-30 | (m) | $62.70M | (m) | (m) |
| 2024-03-31 | (m) | $50.46M | (m) | (m) |
| 2023-12-31 | (m) | $76.01M | (m) | (m) |
| 2023-09-30 | (m) | $461.58M | (m) | (m) |
| 2023-06-30 | (m) | $447.70M | (m) | (m) |
| 2023-03-31 | (m) | $446.14M | (m) | (m) |
| 2022-12-31 | (m) | $412.48M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $26.68M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $38.95M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |